A NO-mediated desensitization of vasoconstrictor responses evoked by stimulation of α 1 -adrenoceptors has been reported in different vessels. We investigated the involvement of each α 1 -adrenoceptor subtype and constitutive NOS isoforms and the influence of ageing and hypertension on this process.
Introduction
Endothelial NO exerts an opposing modulatory effect on the vasoconstriction induced by α 1 -adrenoceptor agonists, since removal of the endothelium or inhibition of NO synthesis increases the α 1 -adrenoceptor-mediated vasoconstriction (Looft-Wilson et al., 2013; Nuñez et al., 2014) . NO also plays an important role in the decreased ability of a vessel to respond to subsequent stimulation by the same agonist, a process called 'NO-mediated desensitization', which had been previously observed on activation of α 1 -adrenoceptors (Hiremath et al., 1991; Kaneko and Sunano; 1993; Hu et al., 1994; Kamata and Makino, 1997; Gürdal et al., 2005) . This NO-mediated desensitization of α 1 -adrenoceptor vasoconstriction may represent a defence mechanism for counteracting the effects of catecholamine overstimulation of vascular smooth muscle. However, the subtype of α 1 -adrenoceptor (α 1A , α 1B or α 1D ) involved in this process has not yet been elucidated.
It is well established that endothelial NOS (eNOS) is the main isoform of NOS present in the endothelium and the primary source of NO, which plays an important role in the regulation of systemic blood pressure and regional blood flow (Moncada et al., 1991; Li et al., 2015) . In the rat aorta, prolonged exposure (6 h) to the α 1 -adrenoceptor agonist phenylephrine (Phe) promotes an increase in eNOS expression, which has been associated with NO-mediated desensitization (Gürdal et al., 2005) .
The neuronal isoform of NOS (nNOS) is also present in vascular endothelial and smooth muscle cells (Boulanger et al., 1998; Brophy et al., 2000; Bachetti et al., 2004; Seddon et al., 2008) and plays an important role in the modulation of vascular tone (Fleming, 2003; Capettini et al., 2008; and arterial pressure (Kurihara et al., 1998) . However, to date, the potential participation of nNOS in the NO-mediated desensitization process has not been elucidated.
Ageing is associated with endothelial dysfunction (Vanhoutte et al., 2016) and a reduction in the expression of eNOS (Chou et al., 1998; Siles et al., 2002; Tanabe et al., 2003; Csiszar, 2009; Zanetti et al., 2010; Gong et al., 2014) and nNOS (Siles et al., 2002; Lekontseva et al., 2012; Jiménez-Altayó et al., 2013) . This would result in a decrease in NO bioavailability and the subsequent loss of NO-mediated desensitization with ageing could have major consequences on the regulation of vascular tone and blood pressure. An accurate analysis of the mechanisms involved in the NO-mediated desensitization of α 1 -adrenoceptorinduced vasoconstriction and the influence of age is essential to better understand the factors involved in the development of age-related cardiovascular pathologies associated with adrenergic dysfunction, such as hypertension and heart failure.
The aims of the present study were to determine (i) the role of each α 1 -adrenoceptor subtype and constitutive NOS isoforms in the NO-mediated desensitization induced by repetitive activation of the α 1 -adrenoceptor and (ii) the influence of ageing and hypertension on this process. For this purpose, we used vessels from young, middle-aged and aged Wistar and spontaneously hypertensive rats (SHR). To translate the results in animal models to human cardiovascular disease, we evaluated the expression of α 1 -adrenoceptor subtypes, eNOS and nNOS in the left ventricle of a group of heart failure patients with a wide age range.
Methods

Patient characteristics
This research conforms to the principles outlined in the Declaration of Helsinki and was performed with the approval of the Ethics Committees of the Universitat de València and of the Hospital La Fe de Valencia (Spain). Patients signed written consents prior to being included in the study.
Failing hearts were obtained from patients undergoing transplantation due to end-stage heart failure (HF, classified according to the New York Heart Association as functional classes III to IV). They all were on a pharmacological therapy for HF with diuretics, β-blockers, ACE inhibitors, i.v. β-agonist drugs or digoxin according to haemodynamic status. Characteristics of the study population are shown in Table 1 .
Following the heart extraction, transmural samples of the explanted failing heart were obtained from the posterior part of the left ventricle (LV) adjacent to the interventricular septum avoiding the areas containing grossly visible scar tissue.
All samples were immediately frozen in liquid nitrogen and stored at À80°C until processed. Samples of the LV included in the present work had been previously used to determine the expression of eNOS and nNOS and related to clinical variables characteristic of heart failure (Vicente et al., 2013) . Here, we extended the study to determine the expression of the three α 1 -adrenoceptor subtypes (α 1A , α 1B and α 1D ).
Animals and tissues
The study was performed in male spontaneously hypertensive (Harlan Interfauna Ibérica, Spain) and Wistar rats (bred in our faculty's animal facility) housed (five animals per cage) under a 12 h light/dark cycle at 22°C and 60% humidity and maintained on standard chow and water ad libitum until they were used for the study. Groups of 16-week-old rats (n = 53 Wistar or n = 6 SHR), 32-week-old rats (n = 6 Wistar or n = 5 SHR), 52-week-old rats (n = 5 Wistar and SHR) and 72-week-old rats (n = 6 Wistar or n = 4 SHR) were deeply anaesthetized with isoflurane and killed by decapitation. LV segments of second-order branches of the superior mesenteric artery [mesenteric resistance arteries (MRA)], tail artery and the thoracic aorta from 16-week-old animals, thoracic aorta from 32 week-old rats and thoracic aorta and LV from all other age groups were removed, cleaned of adipose tissue and placed into Krebs solution (mM): NaCl, 118; KCl, 4.75; CaCl 2 , 1.8; MgCl 2 , 1.2; NaHCO 3 , 25; KH 2 PO 4 , 1.2; glucose, 11; pH = 7.4. In some vessels, the endothelial layer was removed by passing a fine cannula through the lumen.
For the immunofluorescence studies, vessels were fixed with 4% phosphate-buffered paraformaldehyde (pH = 7.4) for 1 h and washed in three changes of PBS solution (pH = 7.4). Arterial segments were placed in PBS containing 30% sucrose overnight, transferred to a cryomold containing Tissue Tek OCT embedding medium and frozen in liquid nitrogen. Some samples of arterial segments and LV were frozen by liquid N 2 immersion and processed for protein or total RNA extraction.
All the experimental procedures complied with guidelines established in the Spanish legislation (Royal Decree RD 1201/2005) and were approved by the Experimental Animal Ethics Committee of the Universitat de València (Spain). Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015) .
Functional experiments
Thoracic aorta (4 mm), tail artery (4 mm) and MRA (2 mm) rings were set up in an isometric organ bath (aorta and tail) or a wire myograph (MRA) (model 610 M, J. P. Trading, Denmark) respectively, filled with Krebs solution at 37°C and gassed with 95% O 2 and 5% CO 2 as described previously (Flacco et al., 2013a ). An initial load of 1 g was applied to the aorta and tail artery, while the internal diameter of MRA was set to a tension equivalent to 0.9 times the estimated diameter at 100 mmHg effective transmural pressure (l 100 = 90-180 μm).
After a 1 h stabilization period, the vessels were contracted with a depolarizing solution (80 mM KCl-Krebs obtained by an isotonic replacement of NaCl by KCl) to check the vessels' functionality. Vessels that contracted less than 3 mN to KCl were discarded. After the washout and the return of a stable baseline, vessels were contracted with the α 1 -adrenoceptor agonist Phe (1 μM) and endothelium integrity was tested with acetylcholine (10 μM). Only the rings that relaxed by more than 70% (Wistar) or 35% (SHR aged animals) to ACh were considered have an intact endothelium; those that failed to relax (<10%) to ACh were considered to have had the endothelium removed.
A concentration-response curve (CRC1) to Phe (1 nM-10 μM) was performed by the addition of cumulative concentrations of the agonist every 10 min. After the preparation had been washed and following a 30 min stabilization period, a second CRC2 to Phe was performed.
The involvement of the endothelium, eNOS and nNOS was studied using either vessels without an endothelium or after exposure to the non-selective NOS inhibitor L-NAME (100 μM), or the selective nNOS inhibitors S-methyl-Lthiocitrulline (SMTC; 1 μM) or 1-(2-trifluoromethylphenyl) imidazole (TRIM; 50 μM), which were added 30 min prior to performing CRC1 to Phe.
The identity of the α 1 -adrenoceptor subtype involved was investigated by using subtype selective antagonists for α 1D -(BMY 7378, 10 nM) and α 1A -(5-methylurapidil, 100 nM) adrenoceptors, which were added to the bath 30 min prior to the Phe CRC1. The concentration of each antagonist was of the same order as its pK B (8.28 for BMY7378, 6.82 for 5-methylurapidil) determined by us in rat aorta (Gisbert et al., 2003) .
The CRCs to Phe are expressed as a percentage of KCl-induced contraction. In some cases, CRC2 to Phe is expressed as a percentage of the maximal response to Phe in CRC1. Data from CRC were plotted using the Graph Pad Software version 4.0 (San Diego, CA, USA), with sigmoid curve fitting (variable slope) performed by non-linear regression; these curves were used to derive the values for E max (the maximal relaxant response) and pEC 50 (Àlog of the agonist concentration needed to produce 50% of E max ).
Immunoblotting
To determine changes in the expression of nNOS and its phosphorylated form (p-nNOS), aortic rings incubated in the organ bath in different experimental conditions were frozen by liquid N 2 immersion and pulverized. The resulting powder was lysed by sonication (Microson ™ XL 2000
Ultrasonic Liquid Processor) in RIPA buffer (50 mM HEPES, 150 mM NaCl, 100 mM NaF, 10% glycerol, 1.5 mM MgCl 2 , 0.1% SDS, 1 mM EGTA, 1% triton and 1% sodium deoxycholate) containing protease (Complete®, Roche Applied Science, Germany) and phosphatase (PhosSTOP®, Roche Applied Science, Germany) inhibitor cocktail. Subsequently, it was centrifuged (16100× g for 15 min at 4°C), and the supernatant was kept frozen at À80°C until used. The protein content was measured by the Bradford method (Bio-Rad Laboratories, Madrid, Spain). Then 15 μg of frozen protein extracts were incubated with the SDSsample buffer (2% SDS, 60 mM Tris-HCl buffer pH 6.8, 5% β-mercaptoethanol, 0.01% bromophenol blue and 10% glycerol), separated on 7% SDS-polyacrylamide gels and transferred to PVDF membranes overnight at 230 mA, using a liquid Mini Trans-Blot® Electrophoretic Transfer Cell system (Bio-Rad Laboratories, Madrid, Spain). Membranes were blocked in 3% BSA in PBS containing 0.1% Tween 20 for 1 h at room temperature with gentle agitation and incubated overnight at 4°C with primary polyclonal antibodies against p-nNOS at Ser 1417 , (equivalent to human incubation with the ECL® western blotting detection reagent (Amersham Biosciences). Membranes were immediately documented and quantified with an Autochemi ™ BioImaging System using the Labworks 4.6 capture software (Ultra-Violet Products Ltd., Cambridge, UK).
Immunofluorescence
Sections of aorta cut on a cryomicrotome (14-μm-thick) were incubated with a rabbit polyclonal antibody against nNOS (1:75; Life Technologies Ltd, Paisley, UK). After being washed, rings were incubated with the secondary antibody, donkey anti-rabbit (1:200) IgG conjugated to Cy ™ 3 (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA), and sections were processed essentially as described previously (Flacco et al., 2013a) . Sections were stained with nuclear dye Hoechst 33342 (0.01 mg·mL À1 ; Sigma-Aldrich, St Louis, MO, USA). Natural autofluorescence elastin images were also taken. Immunofluorescent signals were viewed using an inverted Leica TCS SP5 confocal laser scanning microscope (Heidelberg, Germany). The specificity of the immunostaining was evaluated by omission of the primary antibody. No Cy ™ 3-derived staining under these conditions was observed in the vessel wall.
qRT-PCR
To obtain total RNA, frozen samples were treated as previously described (Montó et al., 2012) . Total RNA was quantified and analysed by running 1 μg of each sample by microfluidic electrophoresis in the Experion ™ -automated electrophoresis system (BioRad, Madrid, Spain) based on the manufacturer's instructions. The software provided us with the RNA concentration (ng·mL À1 ), the 28S/18S ratio and the RNA quality indicator (RQI), which measures RNA integrity by comparing the electropherogram of the RNA samples to a series of standardized degraded RNA samples. The RQI method returns a number of between 10 (intact RNA) and 1 (highly degraded RNA). In our samples, the RQI value was between 7.7 and 9.8. Total RNA using 500 ng and oligo(dT)16 as a primer (250 ng) in diethyl pyrocarbonate (DEPC)-treated water was pre-heated to 70°C and then cooled on ice for cDNA synthesis. The reactions (20 μL) contained ImProm-II ™ reaction buffer, 3 mM MgCl 2 , 20 U of Recombinant RNAsin® Ribonuclease Inhibitor (Promega Corp., Madison USA), 0.5 mM of each deoxynucleoside triphosphate and 1 μL of ImProm-II Reverse Transcriptase (Promega Corp., Madison, USA). They were incubated at 25°C for 5 min (annealing step), followed by an extension step at 42°C for 60 min and a final step at 70°C for 15 min (heat-inactivate). The mRNAs encoding the two constitutive isoforms of NOS (eNOS and nNOS), the three α 1 -adrenoceptor subtypes (α 1A , α 1B and α 1D ) and GAPDH as internal standard were quantified by TaqMan® real-time RT-PCR in a GeneAmp 7500 Fast System (Applied Biosystems, Carlsbad, CA, USA), as previously described (Montó et al., 2012) . The specific primer-probes were as follows:
NOS3 (Hs00167166_m1); NOS1 (Hs00167223_m1); ADRA1A (Hs00169124_m1); ADRA1B (Hs00171263_m1); ADRA1D (Hs00169865_m1) and GAPDH (Hs99999905_m1) for human samples.
Nos3 (Rn02132634_s1); Nos1 (Rn00583793_m1); Adra1a (Rn00567876_m1); Adra1b (Rn01471343_m1); Adra1D (Rn00577931_m1) and Gapdh (Rn99999916_s1) for rat samples.
Real-time PCR reactions were done in 25 μL with TaqMan Universal PCR Master Mix (Applied Biosystems, USA), including 5 μL of diluted RT reaction, and 1.25 μL of 20X TaqMan Gene Expression Assay Mix (250 nM for the probe and 900 nM for each primer). cDNA was amplified following the manufacturer's instructions: one initial hold-step at 95°C for 10 min, a second step with 40 cycles, 15 s at 95°C (denaturation) and 1 min at 60°C (annealing/extension). The targets and reference (Gapdh or GAPDH) were amplified in parallel reactions. The Ct values obtained for each gene were referenced to GAPDH and converted into the linear form using the term 2 -ΔCt ×10 4 as a value directly
proportional to the mRNA copy number.
Statistical analysis
Data are expressed as mean ± SEM and n represents the number of experiments. Differences between two groups were analysed using Student's t-test (paired and unpaired). Differences among three groups were analysed using oneway ANOVA and Newman-Keuls test as post hoc analysis. Spearman correlation test was performed to establish associations between age and experimental variables. Student's t-test, one-way ANOVA and Spearman correlation test were performed using the Graph Pad Prism 4 Software. A probability value of P < 0.05 was considered significant. The data and statistical analyses comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Drugs
The following drugs were obtained from Sigma-Aldrich (St Louis, MO, USA): ACh chloride, (R)-(À) phenylephrine hydrochloride, 5-hydroxytryptamine, L-NAME, SMTC, TRIM, BMY 7378 and 5-methylurapidil. All the drugs were prepared in distilled water, except TRIM which was dissolved in DMSO.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b) .
Results
Fast desensitization of the α 1 -adrenoceptor response in rat aorta
Two consecutive CRCs to Phe (CRC1 and CRC2) were performed in isolated rings of aorta, tail artery and MRA obtained from Wistar rats. In rat aorta, the pEC 50 did not change, but the E max of CRC2 was significantly lower than that of CRC1 ( Figure 1A , Table 2 ), which indicates the BJP C Arce et al.
existence of a desensitization process. This desensitization was not observed in tail artery or in the MRA (Table 2) . When two consecutive CRC to noradrenaline (1 nM to 10 μM) were performed in rat aorta, a desensitization process was obtained, similar to that reported for Phe (results not shown).
Removal of the endothelium ( Figure 1B ), incubation with L-NAME (100 μM) ( Figure 1C ), SMTC (1 μM) ( Figure 1D ) or TRIM (50 μM) ( Figure 1E ) prevented the Phe-induced desensitization, suggesting the participation of NO derived from the endothelial nNOS in this process. Incubation of the aorta with L-NAME (100 μM) increased the CRC1 to Phe and abolished the ACh-induced relaxation, whereas incubation with SMTC (1 μM) or TRIM (50 μM) had no significant effect on the CRC1 to Phe or on the ACh-induced relaxations (Figure 2 ), providing evidence that these agents selectively inhibit nNOS.
In rat aorta, the decrease in the CRC2 E max was observed only when supramaximal concentrations of Phe (3 or 10 μM) were used in the CRC1 for a short time (10 min), but not when the highest concentration of Phe used in CRC1 was 1 μM (Table 2) . However, when Phe 1 μM was present for a longer time (60 min) the E max of CRC2 was also decreased (Table 2) .
To evaluate if the observed desensitization was restricted to responses mediated by stimulation of α 1 -adrenoceptors, two consecutive CRC to 5-HT, or a CRC1 to Phe followed by a CRC2 to 5-HT were performed. The results shown in Table 3 indicate that the desensitization process is exclusively dependent on repeated activation of the α 1 -adrenoceptor.
Figure 1
Fast desensitization of α 1 -adrenoceptor-induced response in rat aorta by repeated stimulation with different concentrations of Phe. Two consecutive concentration response curves (CRC1 or CRC2) to Phe (1 nM-10 μM) were performed in aorta (A) with (E+) or (B) without (EÀ) endothelium, (C) incubated with 100 μM L-NAME (D) incubated with 1 μM SMTC and (E) incubated with 50 μM TRIM. Values are the mean ± SEM of n different animals. *P < 0.05 versus CRC1 E max (Student's unpaired t-test).
To investigate the α 1 -adrenoceptor subtype involved in the nNOS mediated desensitization, we examined the influence of the α 1D -(BMY 7378) and the α 1A -(5-methylurapidil) adrenoceptor subtype selective antagonists and performed the experimental protocol shown in Figure 3A , using concentrations of each antagonist (10 and 100 nM respectively) that are of the same order as their pK B determined in rat aorta in our laboratory (Gisbert et al., 2003) . When we analysed the contractile responses, it was evident that the α 1A subtype was involved in the desensitization. Both antagonists shifted the CRC1 to Phe to the right but had a different effect on the CRC2. Incubation with BMY 7378 before and during CRC1, followed by wash out of the antagonist, did not prevent desensitization in CRC2 ( Figure 3B ), In contrast, incubation with 5-methylurapidil abolished the desensitization process ( Figure 3C ).
Increased nNOS expression contributes to the α 1A -adrenoceptor-mediated desensitization Different experimental approaches ( Figure 4A, C) confirmed the involvement of augmented nNOS activity in the decreased response to stimulation of α 1 -adrenoceptors after repeated exposure to Phe. As Figure 4B shows, the presence of SMTC 1 μM during CRC1 did not affect the desensitization process. In contrast, incubation with SMTC 1 μM, before and during CRC2, prevented the desensitization. Furthermore, the addition of SMTC 1 μM at the top of the CRC1 to Phe induced a slight increase in contractile tone, which was significantly larger when SMTC was added at the top of CRC2 ( Figure 4D ), suggesting that the participation of NO-derived from nNOS is significantly increased after repeated Phe exposure. The addition of L-NAME 100 μM at the top of CRC1 and CRC2 confirmed the increased influence of NO after repeated exposure to Phe ( Figure 4D ).
The expression levels of the genes Nos3 (eNOS) and Nos1 (nNOS) were quantified in aorta, tail artery and MRA. The results obtained indicate that Nos3 was expressed in all vessels whereas Nos1 was present in aorta but not in tail or MRA ( Figure 4E ). The localization of nNOS in the aortic endothelial layer was confirmed by immunofluorescence ( Figure 4F ). The lack of nNOS mRNA expression in MRA from male Wistar rats contrasts with previous results of immunohistochemical studies showing nNOS expression in the endothelium of MRA from female Sprague-Dawley rats (Lekontseva et al., 2011) . This apparent discrepancy could be explained if we consider sex and/or strain differences since nNOS activity in MRA from Sprague-Dawley rats is oestrogen-dependent and was only demonstrated in female rats.
In our hands, the absence of nNOS gene expression in tail artery and MRA would explain the lack of nNOS-mediated desensitization in these vessels.
Mechanisms of nNOS-mediated α 1 -adrenoceptor desensitization
We quantified nNOS and phosphorylated (p)nNOS protein expression in aortic rings pretreated or not with Phe, following the experimental procedure described in Figure 5A . Four different rings were incubated in organ baths under different conditions. The PheA samples were pretreated with Phe (CRC1) and frozen when Phe had been removed; the PheB samples were processed after CRC2 when Phe was still present; Controls A and B were samples performed in parallel but without Phe treatment. nNOS protein expression was higher after pre-exposure to Phe in both conditions, before (PheA) and after (PheB) CRC2. However, increased nNOS phosphorylation was only observed when the agonist was present ( Figure 5B, C) .
nNOS-mediated desensitization is also present in hypertensive animals, but it is lost with ageing
To study the pathophysiological importance of the aortic α 1 -adrenoceptor desensitization, we analysed the role of age and hypertension using aortic rings from normotensive and hypertensive young (16 weeks), adult (32 weeks), In aorta and tail arteries, a different range of concentrations was assayed on CRC1 to Phe. In a group of experiments, the maximal concentration assayed was maintained during a prolonged incubation time (60 min). E max is expressed as a percentage of KCl-induced contraction. Values are the mean ± SEM of n experiments. *P < 0.05 versus CRC1 E max (Student's unpaired t-test).
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middle-aged (52 weeks) and old (72 weeks) Wistar and SHR (Dal-Ros et al., 2012).
The maximal response to Phe was slightly decreased in the aged Wistar rats (90.0 ± 4.8%, n = 6, in 16-week-old rats vs. 75.0 ± 4.7%, n = 6, 72-week-old rats, expressed as % of maximal 80 mM KCl-induced contraction), but the difference was not statistically significant. However, the α 1A -adrenoceptor/nNOS-mediated desensitization observed in aorta was progressively reduced with age and had disappeared in the 52-and 72-week-old Wistar ( Figure 6A ) and SHR ( Figure 6B ). Owing to the small group size of the 52-week-old Wistar and SHR, or 72-week-old SHR animals, no statistics were performed.
The desensitization process observed in the 16-week-old SHR was prevented by SMTC 1 μM (E max Phe CRC2 vs. E max CRC1 = 47.7 ± 7.6% in the absence of SMTC, n = 6, P < 0.05; and 100.9 ± 14.2% in the presence of SMTC, n = 6).
The loss of desensitization in Wistar and SHR with age was accompanied by a partial deterioration of endothelial function, revealed by a reduction in the relaxation induced by ACh in Phe (1 μM) constricted vessels. Age altered the ACh-induced vasodilatation in both strains, but the effect of ageing was markedly stronger in the SHR (Supporting Information Figure S1 ).
Corroborating the lack of the desensitization mechanism observed in functional studies, in aortas from 52-week-old animals previously exposed to Phe (CRC1), nNOS and p-nNOS expression levels were not altered before (PheA) and after (PheB) the CRC2 to Phe (Figure 6C-E) . Owing to the small group size, no statistics were performed.
To determine if an altered expression of α 1A -adrenoceptors could be involved in the attenuation of the desensitization process observed with ageing, we analysed the mRNA levels of the three α 1 -adrenoceptor subtypes (Adra1a, Adra1b and Adra1d) and the two constitutive NOS isoforms, nNOS and eNOS (Nos1 and Nos3) in aorta and LV from young (16 weeks old) and aged (52 and 72 weeks old) Wistar rats. A significant agedependent decrease in Adra1a was observed in aorta and LV from 52-and 72-week-old rats, accompanied by a decrease in Nos1 in aortas from 72-week-old rats. (Figure 7) . The other genes did not follow the same pattern of changes with age: Nos3 did not change in any tissue, Adra1b changed in aorta but not in LV and Adra1d expression was significantly lower in aorta and LV from aged rats (Figure 7) .
Expression of ADRA1A decreases with ageing in human heart
In order to translate the results obtained in rats to the human cardiovascular system, a quantitative analysis of NOS1, NOS3, ADRA1A, ADRA1B and ADRA1D mRNA levels was carried out in the LV from explanted failing hearts of patients with a wide age range.
Spearman's rank correlation tests were performed to establish statistical association between the mRNA values of each gene expression and the age of the patient. As Figure 8 shows, a significant and negative correlation was observed Table 3 Parameters of two consecutive concentration-response curves (CRC1/ CRC2) to 5-HT (10 nM-10 μM) or phenylephrine CRC1/5-HT CRC2 in aorta Effect of preincubation with SMTC, TRIM or L-NAME on CRC to (A) Phe, and (B, C) to ACh in rat aorta from Wistar rats. Values are the mean ± SEM of n = 6 different animals. *P < 0.05 versus CRC1 E max (Student's paired t-test).
between the mRNA levels of the α 1A -adrenoceptor and age, whereas no significant correlation was observed with nNOS, eNOS or with the other two α 1 -adrenoceptor subtypes. On the basis of this negative correlation observed in the human LV, we can propose that a decrease in the expression of α 1A -adrenoceptors occurs with ageing in the human cardiovascular system.
Discussion
The main finding of our work is that endothelial nNOS exerts a modulatory role during repeated α 1 -adrenoceptor-mediated vasoconstriction in aorta, but not in tail artery or MRA. This effect is related to a higher nNOS expression and mediated by activation of the α 1A -adrenoceptor subtype. Experiments with aged animals indicated that the desensitization mechanism as well as the augmented nNOS expression disappear with ageing, resulting in greater vasoconstrictor responses to α 1 -adrenoceptor agonists. The loss of this desensitization response observed in aged animals was accompanied by a significant decrease in the expression of the α 1A -adrenoceptor in aorta and LV. In the explanted LV of heart failure patients, a decreased expression of α 1A -adrenoceptors also occurs with ageing. Together, these findings support the hypothesis that the α 1A -adrenoceptor subtype, through endothelial nNOS-derived NO, may act as a natural 'brake' against the detrimental effects of excessive α 1 -adrenoceptor-induced vasoconstriction.
Endothelial nNOS as a modulator of α 1 -adrenoceptor-mediated contraction in aorta
Prolonged exposure of blood vessels to an α 1 -adrenoceptor agonist up-regulates endothelium-mediated inhibitory mechanisms (Hiremath et al., 1991; Hu et al., 1994; Kamata and Makino, 1997; Gürdal et al., 2005) and increases the expression and activity of eNOS (Gürdal et al., 2005) . The induction of eNOS expression had also been observed when vessels were activated by other vasoconstrictor agonists such as 5-HT, endothelin or angiotensin (Hu et al., 1994 , Seasholtz et al., 1997 Gürdal et al., 2005) , as well as when they were exposed to shear or mechanical stress and haemodynamic changes (Ohara et al., 1995; Ranjan et al., 1995; Xiao et al., 1997; Fleming and Busse, 2003; Jin et al., 2003) . In addition, prolonged exposure (6 h) to Phe decreases the response to subsequent addition of other vasoconstrictor agents as 5-HT (Hu et al., 1994) . Therefore, the eNOS-mediated modulatory mechanism does not seem to depend specifically on α 1 -adrenoceptor activation.
In agreement with the above reported studies, we showed that α 1 -adrenoceptor-mediated vasoconstriction was reduced by previous exposure to α 1 -adrenoceptor agonists in an endothelium and NO-dependent manner. Nevertheless, in the present study differences were established compared with previous observations: (i) the desensitization mechanism occurred earlier (30-60 min compared with 4-6 h) following first exposure to high concentrations of an α 1 -adrenoceptor agonist; (ii) it was dependent on specific and repeated α 1 -adrenoceptor activation, as it was not present when vessels were stimulated with other vasoconstrictor agents; (iii) preexposure to Phe did not modify the response to the later addition of other vasoconstrictor agents as 5-HT; (iv) it was present in aorta, but not in tail artery or MRA; and (v) it involved an increased protein expression of nNOS accompanied by nNOS phosphorylation, with no changes in eNOS expression/function.
The role of endothelial nNOS as a modulator of the α 1 -adrenoceptor-mediated response and the desensitization mechanism is supported by the following experimental findings:
(i) The desensitization mechanism was abolished either by endothelial removal or by selective nNOS inhibition with SMTC, at concentrations not affecting eNOS activity.
Figure 4
Phe-induced desensitization in rat aorta depends on nNOS-derived NO. (A) Schematic drawing showing the procedure used in (B). Two consecutive CRC (CRC1 or CRC2) to Phe (1 nM-10 μM) were performed in aorta in the presence or absence of SMTC (1 μM) added 30 min before CRC1 or CRC2. Values are the mean ± SEM of n different animals. *P < 0.05 versus CRC1 E max (Student's paired t-test). (C) Schematic drawing showing the procedure used in (D). Increases in tone observed after addition of SMTC (1 μM) or L-NAME (100 μM) on the sustained contractile response to Phe 10 μM in CRC1 or CRC2. Values are the mean ± SEM of n = 5 different animals. *P < 0.05 versus CRC1 (Student's unpaired t-test).
(E) mRNA levels of Nos1 and Nos3 in rat aorta, tail and MRA. Values are expressed as 2 ÀΔCt ×10 4 using Gapdh as a housekeeping gene and represent the mean ± SEM of five different animals. (F) Representative immunofluorescence photomicrographs of the confocal microscopic sections of the nNOS (red) in aorta (n = 3 different animals). Natural autofluorescence of elastin (green) and nuclear staining (blue) are also shown. AC, adventitial cell; EC, endothelial cell; EL, elastic lamina; SMC, smooth muscle cell.
(ii) The presence of nNOS in the aortic endothelial layer was confirmed by immunofluorescence, as previously described (Capettini et al., 2008; Lekontseva et al., 2012) . (iii) A slight increase in the vasoconstrictor response was observed when SMTC was added on top of the maximal contraction obtained during the first exposure to Phe, indicating a minor role for nNOSderived NO release. In contrast, when SMTC was added on top of the second CRC to Phe, a larger increase in the vascular tone was observed suggesting a greater participation of nNOS-mediated NO release after agonist pre-exposure. (iv) An increase in overall nNOS protein expression was detected in response to repeated α 1 -adrenoceptor activation. (v) It is known that phosphorylation at Ser 1412 , analogous to the Akt-dependent phosphorylation site of eNOSSer 1177 , enhances nNOS activity (Zhou and Zhu, 2009 ).
In the aorta, α 1 -adrenoceptor activation increased the level of the Ser 1412 -phosphorylated nNOS relative to that of the un-phosphorylated nNOS.
The α 1A -adrenoceptor is the subtype involved in the desensitization process
It is well known that among the three α 1 -adrenoceptor subtypes present in the aorta, α 1D is the main subtype involved in contractile responses, the α 1A subtype participates but has a minor role, whereas the α 1B -adrenoceptor has not been implicated in the control of vascular tone so far (Flacco et al., 2013b) . A selective α 1D -adrenoceptor antagonist (BMY 7378) did not affect, while a selective α 1A -adrenoceptor antagonist (5-methylurapidil) prevented the desensitization process, suggesting that it is mediated by activation of α 1A -adrenoceptors. The α 1A subtype needs higher concentrations of the agonist than the α 1D subtype to be activated (Flacco et al., 2013b) . Therefore, differences in sensitivity to agonists
Figure 5
Increased endothelial nNOS expression is responsible for the Phe-mediated desensitization in aorta. (A) Schematic drawing showing the experimental procedure used to study the mechanism of the α 1 -adrenoceptor-mediated desensitization: None (control), or two consecutive CRC1 and CRC2 to Phe (1 nM-10 μM) were performed in aortic rings incubated in an organ bath. W, wash. Samples to immunoblot were obtained in different conditions: in Phe-treated rings, (PheA) before performing CRC2, or (PheB) at the end of CRC2; in untreated rings, Control A or Control B, performed in parallel with PheA or PheB samples. (B) Representative immunoblot of p-nNOS, nNOS and actin in aortic rings processed as described in Methods and (C) relative quantification of nNOS/actin and p-nNOS/nNOS. Data are expressed as a percentage versus control and represent the mean ± SEM of five different animals. *P < 0.05 versus control (Student's paired t-test).
between subtypes reaffirm the hypothesis that the α 1A -adrenoceptor is the subtype responsible for desensitization, which only appears when high concentrations of the agonist are employed.
These results functionally explain the interaction between α 1A -adrenoceptors and nNOS previously reported by other authors (Pupo and Minneman, 2002) and support the presence, in rat aorta, of a modulatory nNOS-dependent mechanism mediated by the minor α 1A subtype, which attenuates vasoconstriction derived from significant concentrations of circulating cathecholamines. Ciccarelli et al. (2008) had previously reported that endothelial cells from rat aorta express α 1A -adrenoceptors (but not α 1D -adrenoceptors), which suggests that α 1A -adrenoceptors directly regulate the activity of the endothelial nNOS.
Influence of age on the α 1A -adrenoceptor/ nNOS-mediated desensitization Ageing is associated with vascular alterations that closely resemble those of hypertension. In fact, arterial changes in young hypertensive patients mimic those in old normotensive individuals and ageing may affect the severity of vascular damage in hypertension, indicating close interactions between biological ageing and an elevation in Figure 6 Phe-mediated desensitization in aorta is lost with age. Two consecutive CRC1 and CRC2 to Phe (1 nM-10 μM) were performed in aortic rings incubated in an organ bath. The figures show the CRC2 in Wistar (A) and SHR (B) animals at different ages (16, 32, 52 and 72 weeks old). Values are the mean ± SEM of n different animals. *P < 0.05 versus CRC1 E max (Student's paired t-test). (C) Schematic drawing showing the experimental procedure used to obtain samples in different conditions: None (control), or two consecutive CRC1 and CRC2 to Phe (1 nM-10 μM) were performed in aortic rings incubated in an organ bath; W, wash. In Phe-treated rings, samples were obtained before (PheA) or at the end (PheB) of CRC2; in untreated rings, Control A or Control B, samples were obtained in parallel with the PheA or PheB samples. (D) Representative immunoblot of p-nNOS, nNOS and actin in aortic rings from 52-week-old animals, processed as described in Methods, and (E) relative quantification of nNOS/actin and p-nNOS/nNOS. Data are expressed as a percentage versus control and represent the mean ± SEM of three different animals.
blood pressure (Taddei et al., 1997; Harvey et al., 2015) . As with ageing, experimental and human hypertension show a reduction in endothelium-dependent vasodilatation, decreased NO bioavailability and NOS uncoupling (Harvey et al., 2015) . Given this background, we extended our study to determine if the α 1A -adrenoceptor/nNOS-dependent desensitization mechanism was present in aortic rings from adult (32 weeks), middle-aged (52 weeks) and old (72 weeks) Wistar and SHR (Dal-Ros et al., 2012) .
Previous observations indicate a decrease in α 1A -adrenoceptor expression/function with ageing (Yono et al., 2006; Cao and Li, 2009 ). However, conflicting results have been reported for nNOS expression. In tissues such as rat cerebral cortex and cerebellum (Siles et al., 2002) and mouse mesenteric arteries (Jiménez-Altayó et al., 2013) , mRNA levels for nNOS decline with ageing, whereas in rat aorta, no change in nNOS levels was observed with ageing (Lekontseva et al., 2012) .
Our results in rat aorta agree with previous observations that indicate a decline in endothelial function, more evident in SHR animals, and a decrease in nNOS and α 1A -adrenoceptor expression with age and extend the understanding of the functional consequences of these alterations. Indeed, in aorta from aged animals, the Figure 7 mRNA levels of Nos1, Nos 3 and the three Adra1 subtypes (Adra1a, Adra1b and Adra1d) in (A) aorta and (B) left ventricle from 16 (n = 10), 52 (n = 5) and 72 (n = 5)-week-old Wistar rats. mRNA levels are expressed as 2 ÀΔCt ×10 4 using Gapdh as a housekeeping gene and represent the mean ± SEM of n different animals. *P < 0.05 versus 16-week-old animals (one-way ANOVA data analysis followed by Newman-Keuls).
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decreased expression of the α 1A -adrenoceptor subtype paralleled the gradual loss of desensitization. Therefore, the absence of α 1A -adrenoceptor/nNOS-mediated desensitization in aged vessels could be explained by the progressive decreased expression of the α 1A -adrenoceptor subtype. Similar age-dependent changes in the desensitization mechanism were observed in normotensive Wistar and SHR rats, indicating that ageing, but not hypertension, is associated with the loss of α 1A -adrenoceptor/nNOS-mediated desensitization.
The results obtained in rat aorta and LV could be translated to humans as, in samples from the LV of heart failure patients, a significant and negative correlation was found between the expression of ADRA1A with age. Therefore, we propose that a parallel and progressive loss in the desensitization mechanism mediated by α 1A -adrenoceptors could also be expected in the human cardiovascular system. In this regard, it is interesting to note that, in spite of the reduction in the expression of some adrenoceptors with age, a chronic increase in sympathetic nerve-mediated vascular tone in conduit arteries is associated with ageing in humans (Casey et al., 2012) . This elevated vascular tone could be due, at least in part, to the loss of the modulatory mechanism mediated by the α 1A -adrenoceptor/ nNOS pathway.
Figure 8
Graphical representation of the correlation observed between the mRNA levels of NOS1, NOS3 and ADRA1 subtypes (ADRA1A, ADRA1B and ADRA1D) and age in the left ventricle of explanted human failing hearts. Significant Spearman correlation (P < 0.05) is represented by a continuous line. mRNA levels are expressed as 2 ÀΔCt ×10 4 using GAPDH as a housekeeping gene. Line fits were generated using linear regression.
